Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Biologics Prices Hong Kong IPO at $511 Million

publication date: Jun 6, 2017
WuXi Biologics priced its Hong Kong IPO at the top of the range, raising $511 million, according to numerous sources. Demand for the offering was strong, caused by the WuXi pedigree and the fast growing revenues of the biologics business-- up 91% in the first nine months of 2016. The WuXi Biologics offering was 30 times oversubscribed, potential cornerstone investors were turned away, and underwriters closed their books early. The offering values WuXi Biologics at $3 billion, and the new shares are expected to begin trading in Hong Kong on June 13. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here